For instance, targeting CAFs-derived CXCL12 with the administration of AMD3100, the inhibitor of the CXCL12 receptor, revealed the antitumor effects in pancreatic cancer [66]. This evidence concerns the gene CXCL12 and familial pancreatic carcinoma.